证券代码： 300463 证券简称：迈克生物 迈克生物股份有限公司投资者关系活动记录表 编号：2025-004 | 投资者关系活动 | 分析师会议 □特定对象调研 □ | | --- | --- | | 类别 □ | 媒体采访 √ 业绩说明会 | | □ | 新闻发布会 □ 路演活动 | | □ | 现场参观 | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 投资者网上提问 | | 人员姓名 | | | 时间 2025 | 年 月 日 下午 9 12 (周五) 14:00~17:00 | | 地点 | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net） | | | 采用网络远程的方式召开业绩说明会 | | 上市公司接待人 | 1、董事会秘书史炜 | | 员姓名 | 2、财务负责人尹珊 | | | 3、证券事务代表张文君 | | | 投资者提出的问题及公司回复情况 | | | 公司就投资者在本次说明会中提出的问题进行了回复： | | | 1、迈克生物的流水线，仪器设备的装机速度正在放缓是什 | | | 么原因呢？ | | | 尊敬的投资者，您好！公司流水线和 ...

Group 1: Financial Performance - In 2024, the company achieved revenue of CNY 2.549 billion, with a net profit of CNY 127 million, representing a decline of 11.98% and 59.44% year-on-year respectively [5] - In Q1 2025, the company reported revenue of CNY 510 million and a net profit of CNY 24 million, down 17.22% and 80.09% year-on-year [5] - The revenue from agency products in 2024 was CNY 612 million, while revenue from self-developed products was CNY 1.913 billion, with a growth of 1.75% in self-developed product sales [5] Group 2: Product Performance - In 2024, self-developed immunological reagents generated CNY 1.029 billion in revenue, an increase of 8.04% year-on-year; biochemical reagents generated CNY 499 million, a decrease of 12.53%; and clinical testing reagents generated CNY 214 million, an increase of 21.70% [5] - In Q1 2025, self-developed product sales revenue was CNY 407 million, down 3.23% year-on-year, with immunological reagents at CNY 210 million (down 4.20%), biochemical reagents at CNY 95 million (down 26%), and clinical testing reagents at CNY 49 million (stable) [6] Group 3: Profitability and Cost Management - The overall gross margin for 2024 was approximately 55%, with a decline of about 1 percentage point in Q1 2025 compared to Q1 2024 [7] - The gross margin for self-developed products decreased by 4.76 percentage points, while the average gross margin for self-developed reagents remained stable at around 80% [9] - In 2024, operational expenses were effectively controlled, with sales expenses down about 1%, management expenses down about 10%, and financial expenses down about 30% [10] Group 4: Business Strategy and Market Trends - The company is focusing on the separation of agency business and enhancing self-developed products, with a strategic shift towards automated laboratory solutions [5] - The impact of national policies such as medical insurance reform and centralized procurement is expected to gradually manifest, with an estimated 20%-30% impact on overall testing volumes in the terminal market [14] - The company plans to limit the proportion of agency products to below 10% in the future, as the revenue from agency products has significantly decreased [20] Group 5: International Business and Future Outlook - In 2024, overseas sales revenue reached CNY 160 million, a year-on-year increase of nearly 60%, with Q1 2025 overseas sales revenue close to CNY 50 million, up 90% [15] - The company is optimistic about future overseas sales and plans to establish a new overseas sales subsidiary in 2025 [15] - The company anticipates that the next two to three years will be critical for industry development, with a focus on enhancing market share in both domestic and international markets [21]